Relugolix Nitroso Impurity 1

It is one of impurity present in Relugolix, Relugolix is a gonadotropin-releasing hormone receptor antagonist, Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. the physiologic effect of relugolix is using Decreased GnRH Secretion. which is used for androgen deprivation therapy in the treatment of advanced prostate cancer.

Additional information

Catalogue No.

VE009886

CAS No.

N/A

Molecular Formula

C28H24F2N8O6S

Molecular Weight

638.6 g/mol

IUPAC Name

1-(4-(1-(2, 6-difluorobenzyl)-3-(6-methoxypyridazin-3-yl)-5-((methyl(nitroso)amino)methyl)-2, 4-dioxo-1, 2, 3, 4-tetrahydrothieno[2, 3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea

Status

In-stock

References

Saad, F., & Shore, N. D. (2021). Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology, 13, 175883592199858. https://doi.org/10.1177/1758835921998586